Observations from Surveillance, Epidemiology, and End Results (SEER) data indicate the majority of ER+/HER2-cancers are low-intermediate risk following RS testing [16], and may be spared chemotherapy prescription [17,18]. This evidence concerns the gene ESR1 and cancer.